Medication-overuse headache: can anti-CGRP monoclonal antibodies replace withdrawal?
Anti-CGRP antibodies offer a targeted strategy capable of interrupting the cycle of overuse and sensitization underlying MOH. Early initiation of anti-CGRP therapy during ongoing overuse appears effective and well tolerated, but long-term outcomes are likely improved when treatment is accompanied by patient education and, in selected cases, structured withdrawal.
Authors
- Lanfranco Pellesi (ORCID: https://orcid.org/0000-0003-4137-5039)
- Alberto Boccalini
- Flavia Lo Castro (ORCID: https://orcid.org/0000-0002-8572-3421)
- Simona Guérzoni (ORCID: https://orcid.org/0000-0001-9589-2782)
- Rossana Allamprese
Institutions
- University of Southern Denmark (DK)
- Azienda Ospedaliero-Universitaria di Modena (IT)
Publication Details
- Journal
- Expert Review of Neurotherapeutics
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1080/14737175.2025.2596783
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00